Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 includes all 13 serotypes in PCV13, along with seven additional serotypes “that are responsible for a substantial amount of the residual disease burden,” he added.

The study compared VAX-31 to PCV20 in 1,015 healthy adults aged 50 and older. The company has selected VAX-31 to advance to an adult Phase 3 program.

At the 2.2mcg dose, VAX-24 met the standard OPA response non-inferiority criteria (1) for all 20 serotypes common with PCV20, of which 16 serotypes (3, 4, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B ...